Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1 - Wikidata - awgldk - TriplyDB

Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1

Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1

http://www.wikidata.org/entity/Q27666407

about

HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 Structural Analysis of Human and Macaque mAbs 2909 and 2.5B: Implications for the Configuration of the Quaternary Neutralizing Epitope of HIV-1 gp120 Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India Immune-correlates analysis of an HIV-1 vaccine efficacy trial HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes.B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies.Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody.Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16.Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design Basic research in HIV vaccinology is hampered by reductionist thinking.Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.Germline-targeting immunogens.Optimization of multi-epitopic HIV-1 recombinant protein expression in prokaryote system and conjugation to mouse DEC-205 monoclonal antibody: implication for in-vivo targeted delivery of dendritic cells.Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops Simultaneous surface display and secretion of proteins from mammalian cells facilitate efficient in vitro selection and maturation of antibodies.Structural Insights from HIV-Antibody Coevolution and Related Immunization Studies

P2860

Q27022055-C81EE45C-748F-48C7-BC17-B17A59679B12 Q27644478-A245C0DB-5A38-4210-AD75-52213A164F3B Q27667819-4313A2C6-1EBE-45A2-BD1C-41BE046F39CC Q27676728-1AF2915A-DFE9-4CEE-8E6E-A1DFC57B803C Q27677941-E4D12FA8-46EC-4611-B4BF-7FC5AFC18321 Q28483205-05DD02EA-9770-441F-989C-C0F242116CA9 Q29617377-9EF1FFD9-69B9-4715-A308-927F2E2335FF Q30355260-D9738DF2-2161-4019-A9EE-70769EA8F607 Q34164923-85B371D1-68BC-4684-96B6-AD8B4F7EA664 Q34270980-25F4E138-F28F-472B-84C2-D4A43BD948A3 Q34273373-38B8DA75-FB51-4378-8CE6-4D1ED107D275 Q34303849-0DCD1DE8-8C18-4F91-8A09-56191D29AA91 Q34562259-601A3465-C2E7-4109-8862-4011F504FE8B Q34637968-404757DD-4A48-4A1D-8806-F0923B3E7545 Q34915786-CA089B6E-405B-47E1-A242-59ED88041F10 Q35018061-C8687C27-356E-4C61-A85F-BC03D7079E25 Q35077716-E4F912F9-A8FB-4F1F-82A6-B819B7E33A50 Q35124761-85843615-F47B-421B-BEFD-8D08BE280E0A Q35192886-ABC854C0-3610-4868-A999-69DDFFC1AB6C Q35382871-039D4551-8B7B-4951-AFA0-7AFD34FFE4D0 Q35603504-1DD3097E-BD3B-4475-8E99-BD1270DB5FFF Q35667479-033F7D84-1977-4109-AD20-31EB4C347905 Q36447540-B9F19111-44A2-429F-8DB0-F915156F7254 Q38025633-4D65F6C6-FF99-4C31-A5BA-E7CF38F5FCF3 Q38046828-B9389A9B-6EF4-4178-AE16-185D643BEF22 Q38631979-17DA82E8-6C86-4F5F-8048-482068E7A8BF Q38764547-D0B2F428-86E9-4413-BFC3-9269250AB172 Q42136176-24FC2854-9FE6-46B5-B7F7-D98242E6B069 Q42181481-7FDB7555-978C-4E35-94FB-E81857D9071C Q43097910-7198D87C-1A61-445D-91E6-AF24049EA780 Q57093739-265BFB4A-2454-4F90-B5B4-2E106D7D0226

P2860

Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1

http://www.wikidata.org/entity/Q27666407

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Crystal Structure of Human Ant ...... That Potently Neutralize HIV-1

@ast

Crystal Structure of Human Ant ...... That Potently Neutralize HIV-1

@en

Crystal Structure of Human Ant ...... That Potently Neutralize HIV-1

@nl

type

label

Crystal Structure of Human Ant ...... That Potently Neutralize HIV-1

@ast

Crystal Structure of Human Ant ...... That Potently Neutralize HIV-1

@en

Crystal Structure of Human Ant ...... That Potently Neutralize HIV-1

@nl

prefLabel

Crystal Structure of Human Ant ...... That Potently Neutralize HIV-1

@ast

Crystal Structure of Human Ant ...... That Potently Neutralize HIV-1

@en

Crystal Structure of Human Ant ...... That Potently Neutralize HIV-1

@nl

P1433

Q27666407-4CF8418F-5A6B-42D3-AA8C-A1BA449D8E56

P1476

Q27666407-AFF79B44-FCFE-4DA5-89F1-A7BCCEF02D9B

P2093

Q27666407-0A72DC23-84BD-4A0B-8D3D-2310A30A9FFB

Q27666407-15D6684B-5E2A-46C0-BFAC-47168CC53242

Q27666407-1B04E742-51F9-4C5C-B350-7E3C0326A62D

Q27666407-262C5A06-3C83-48F4-941E-A5A5CC0749EB

Q27666407-2E99C38C-F97B-4FC6-866B-C1C322F2F4EC

Q27666407-4A49E9EE-1096-47D3-93B5-A6F1AE7CEB59

Q27666407-6219922D-902A-460C-A691-DDA5EC60C76B

Q27666407-626378DD-37EE-431A-8971-F8495D3DBA33

Q27666407-6FE5C25C-8F6E-4402-BCC7-1B49F58B2CB8

Q27666407-7461163D-DCAB-4C8D-9D11-B7714583B3CC

P2860

Q27666407-27A56F66-4752-4776-9413-020C0D3C4813

Q27666407-2B9368F8-6D4A-466C-AAED-CAD53F71E8C1

Q27666407-336779DA-5180-4E78-BE6C-5545868280D5

Q27666407-339D91BF-9E12-4BC9-B617-133D73089CAB

Q27666407-34021AA4-2B25-45CC-A599-5810C5FFFEA6

Q27666407-34A6254B-5357-4FED-9E84-9CDCD5C80ACA

Q27666407-376D8959-FB20-4FBB-98D8-3D49AED4E122

Q27666407-3A0CA42E-F5B6-41B0-85BD-034D44C82DA4

Q27666407-43BA43DF-D277-47C9-A975-B26D453AA52D

Q27666407-44802779-47AB-4141-9270-769645C0A260

P304

Q27666407-CF6DE424-1396-49EB-B533-4CACAEB59E50

P31

Q27666407-E5A0FABD-11F4-4A08-906C-BF40B3C4DB23

P356

Q27666407-C0D3529C-F13F-427A-8035-E41B845875DA

P433

Q27666407-4D19A1BE-DFFA-48CC-8EA1-57D97B808ADE

P478

Q27666407-1ADCEA32-A262-4B8C-A723-3AEE1920B757

P50

Q27666407-43AF8C44-DAF7-4E3B-A83C-48752134F491

P577

Q27666407-545526C5-4022-44C2-95B7-405188666EF3

P698

Q27666407-E9966B97-7602-4A18-B22C-50E9161CBA8B

P921

Q27666407-5B3EEA80-74E3-41B1-BCFD-C9BDAF433164

Q27666407-B7DC8447-0D9E-4357-BB6A-EDB18CA53D98

P932

Q27666407-BC16DF3F-013B-4FC2-88DD-A9680E2F44F5

P356

P1433

Journal of Virology

P1476

Crystal Structure of Human Ant ...... That Potently Neutralize HIV-1

@en

P2093

Anita Changela

http://www.w3.org/2001/XMLSchema#string

Baoshan Zhang

http://www.w3.org/2001/XMLSchema#string

Glenn A Nardone

http://www.w3.org/2001/XMLSchema#string

James E Robinson

http://www.w3.org/2001/XMLSchema#string

Jiang Zhu

http://www.w3.org/2001/XMLSchema#string

Leonidas Stamatatos

http://www.w3.org/2001/XMLSchema#string

Marie Pancera

http://www.w3.org/2001/XMLSchema#string

Miroslaw K Gorny

http://www.w3.org/2001/XMLSchema#string

Peter D Kwong

http://www.w3.org/2001/XMLSchema#string

Sanjay Phogat

http://www.w3.org/2001/XMLSchema#string

P2860

TM-align: a protein structure alignment algorithm based on the TM-score

MolProbity: all-atom structure validation for macromolecular crystallography

Structural definition of a conserved neutralization epitope on HIV-1 gp120

Improved methods for building protein models in electron density maps and the location of errors in these models

Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D

Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens

Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

P304

2524-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02335-10

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21191009

http://www.w3.org/2001/XMLSchema#string

P921

crystal structure

P932

3067962

http://www.w3.org/2001/XMLSchema#string